Meyer Andrew Hollman Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
6
Insider Sells Sum
$3.48M

Insider Activity of Meyer Andrew Hollman

According to the SEC Form 4 filings, Meyer Andrew Hollman, being in a position of

  1. Chief Business Officer at Janux Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 8545 shares for $235,718,
    over all time since 2024-09-27, has bought 0 shares, and sold 104812 shares for $4.31M.

Biography of Meyer Andrew Hollman

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $235,7183100

Comparison of Insiders on Amount of Buys and Sells

2026-01-02SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
1,879
0.0031%
$13.73$25,799+9.19%
2025-12-01SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
3,333
0.0054%
$32.98$109,929-56.25%
2025-11-14SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
3,333
0.0061%
$30.00$99,990-48.98%
2025-10-28SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
16,665
0.0341%
$30.06$500,987-49.46%
2025-05-01SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
3,333
0.0056%
$32.03$106,745-27.49%
2025-05-01SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
2,933
0.0049%
$31.95$93,703-27.49%
2025-04-21SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
3,334
0.0069%
$30.00$100,020-19.76%
2025-03-03SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
3,334
0.0059%
$32.15$107,174-23.34%
2025-02-03SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
3,334
0.0056%
$42.29$140,999-40.08%
2025-01-02SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
13,334
0.0234%
$54.88$731,785-51.23%
2024-09-27SaleJanux Therapeutics, Inc.
JANX
Chief Business Officer
50,000
0.0945%
$45.96$2.3M-34.21%
Total: 11
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.